Depending on the drug, it may also lower cardiovascular risk or the likelihood of kidney complications in those with type 2 diabetes, ease heart failure symptoms, reduce liver fat, improve metabolic dysfunction, and lessen the severity of sleep apnea
Lancet Diabetes Endocrinol 6(8):605617 Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018b) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
This suggests the presence of compensatory mechanisms involving other hypothalamic or extra-hypothalamic regions [80,93]
Central nervous system agents in medicinal chemistry